바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
사전등록 바로가기
 

logo

메뉴
search

ISSN : 0376-4672

논문 상세

이전 다음
논문 투고

60권 11호

약물 관련 악골 괴사증 (MRONJ) 환자에서 Pentoxifylline and Tocopherol의 효과: 문헌고찰

Effect of pentoxifylline and tocopherol for MRONJ patients: A systematic review

김무경 (고려대학교 구로병원 구강악안면외과)
김현제 (고려대학교 구로병원 구강악안면외과)
김동혁 (고려대학교 구로병원 구강악안면외과)
이의석 (고려대학교 구로병원 구강악안면외과)
임호경 (고려대학교 구로병원 구강악안면외과)
대한치과의사협회지 / The Journal of the Korean Dental Association, (P)0376-4672; (E)2713-7961
2022, v.60 no.11, pp.694-703
https://doi.org/10.22974/jkda.2022.60.11.002
김무경, 김현제, 김동혁, 이의석, & 임호경. (2022). 약물 관련 악골 괴사증 (MRONJ) 환자에서 Pentoxifylline and Tocopherol의 효과: 문헌고찰. 대한치과의사협회지, 60(11), 694-703, https://doi.org/10.22974/jkda.2022.60.11.002

Abstract

MRONJ (medication related osteonecrosis of the jaw) is a disease characterized by necrosis of the jaw that occurs after administration of anti-resorptive or anti-angiogenic drugs. However, etiology and effective treatment methods of MRONJ are not yet clearly identified. In this study, a systematic review was conducted to investigate the effects of pentoxifylline and tocopherol on MRONJ. A total of 5 clinical studies using pentoxifyllie and tocopherol in MRONJ patients among the papers registered in Pubmed/medline were reviewed. Pentoxifyllie and tocopherol were used for therapeutic purposes in 32 patients, and the mean age was 68 years for men and 74.21 years for women. Of the 32 patients, 20 patients were stage 2, 11 patients were stage 3, and one patient was stage 0. In the most cases, the triggering factor was extraction. All patients com plained of pain in the lesion area before drugs administration. The average follow-up period was 10.6 months. After drugs administration, 29 patients (90.6%) showed improvement in symptoms in terms of bone exposure and pain. Administration of pentoxifylline and tocopherol in MRONJ may improve symptoms of pain and bone exposure. However, it seems that additional studies on the appropriate use and dose, timing and duration of administration are needed.

keywords
Medication-related osteonecrosis, Pentoxifylline, Tocopherol, Jaw

참고문헌

1.

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-7. http://doi.org/10.1016/s0278-2391(03)00720-1.

2.

2. Sivolella S, Lumachi F, Stellini E, Favero L. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res. 2013;33(5):1793-7.

3.

3. Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg. 2013;17(4):303-6. http://doi.org/10.1007/s10006-012-0379-9.

4.

4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56. http://doi.org/10.1016/j.joms.2014.04.031.

5.

5. Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(2):192-200. http://doi.org/10.1016/j.oooo.2012.05.017.

6.

6. Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049-57. http://doi.org/10.1016/j.oraloncology.2014.08.016.

7.

7. Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients:a systematic review. Int J Oral Maxillofac Surg. 2015;44(5):568-85. http://doi.org/10.1016/j.ijom.2015.01.026.

8.

8. Tsao C, Darby I, Ebeling PR, Walsh K, O'Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013;71(8):1360-6. http://doi.org/10.1016/j.joms.2013.02.016.

9.

9. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341-7. http://doi.org/10.1093/annonc/mdr435.

10.

10. Bocanegra-Perez S, Vicente-Barrero M, Knezevic M, Castellano-Navarro JM, Rodriguez-Bocanegra E, Rodriguez-Millares J, et al. Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2012;41(11):1410-5. http://doi.org/10.1016/j.ijom.2012.04.020.

11.

11. Ceponis P, Keilman C, Guerry C, Freiberger JJ. Hyperbaric oxygen therapy and osteonecrosis. Oral Dis. 2017;23(2):141-51. http://doi.org/10.1111/odi.12489.

12.

12. Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O, et al. Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg. 2011;69(9):2465-72. http://doi.org/10.1016/j.joms.2011.02.078.

13.

13. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg. 2007;65(7):1321-7. http://doi.org/10.1016/j.joms.2007.03.019.

14.

14. Martos-Fernandez M, Saez-Barba M, Lopez-Lopez J, Estrugo-Devesa A, Balibrea-Del-Castillo JM, Bescos-Atin C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):431-9. http://doi.org/10.1016/j.oooo.2018.02.004.

15.

15. Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys. 2011;80(3):832-9. http://doi.org/10.1016/j.ijrobp.2010.03.029.

16.

16. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994;83(2):262-7.

17.

17. Magnusson M, Gunnarsson M, Berntorp E, Bjorkman S, Hoglund P. Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. Eur J Pharmacol. 2008;581(3):290-5. http://doi.org/10.1016/j.ejphar.2007.11.054.

18.

18. Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med. 2014;72:76-90. .http://doi.org/10.1016/j.freeradbiomed.2014.03.035

19.

19. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432. http://doi.org/10.1002/14651858.CD012432.pub2.

20.

20. Varoni EM, Lombardi N, Villa G, Pispero A, Sardella A, Lodi G. Conservative Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Retrospective Cohort Study. Antibiotics (Basel). 2021;10(2). http://doi.org/10.3390/antibiotics10020195.

21.

21. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34(1):50-97. http://doi.org/10.2165/00003495-198734010-00003.

22.

22. Delanian S, Lefaix JL. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol. 2004;73(2):119-31. http://doi.org/10.1016/j.radonc.2004.08.021.

23.

23. Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck. 2005;27(2):114-23. http://doi.org/10.1002/hed.20121.

24.

24. D'Souza J, Lowe D, Rogers SN. Changing trends and the role of medical management on the outcome of patients treated for osteoradionecrosis of the mandible: experience from a regional head and neck unit. Br J Oral Maxillofac Surg. 2014;52(4):356-62. http://doi.org/10.1016/j.bjoms.2014.01.003.

25.

25. Patel V, Gadiwalla Y, Sassoon I, Sproat C, Kwok J, McGurk M. Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck. Br J Oral Maxillofac Surg. 2016;54(5):547-50. http://doi.org/10.1016/j.bjoms.2016.02.024.

26.

26. Delfrate G, Mroczek T, Mecca LEA, Andreis JD, Fernandes D, Lipinski LC, et al. Effect of pentoxifylline and alpha-tocopherol on medication-related osteonecrosis of the jaw in rats: Before and after dental extraction. Arch Oral Biol. 2022;137:105397. http://doi.org/10.1016/j.archoralbio.2022.105397.

27.

27. Lindberg AE. Vitamin E: Nutrition, Side Effects, and Supplements. New York: Nova Science Publishers, Inc; 2011.

28.

28. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis:pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(5):593-6. http://doi.org/10.1016/j.tripleo.2010.05.067.

29.

29. Seo MH, Eo MY, Myoung H, Kim SM, Lee JH. The effects of pentoxifylline and tocopherol in jaw osteomyelitis. J Korean Assoc Oral Maxillofac Surg. 2020;46(1):19-27. http://doi.org/10.5125/jkaoms.2020.46.1.19.

30.

30. Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(4):455-9. http://doi.org/10.1016/j.oooo.2016.06.019.

31.

31. Magremanne M, Reychler H. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. J Oral Maxillofac Surg. 2014;72(2):334-7. http://doi.org/10.1016/j.joms.2013.06.188.

logo

논문 투고
OA 정책